1. HoeijmakersJ (2009) DNA damage, aging, and cancer. N Engl J Med 361: 1475–1485.
2. HewishM, LordCJ, MartinSA, CunninghamD, AshworthA (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7: 197–208.
3. RoyR, ChunJ, PowellSN (2012) BRCA1 and BRCA2: important differences with common interests. Nat Rev Cancer 12: 372.
4. McKinnonPJ (2009) DNA repair deficiency and neurological disease. Nature reviews Neuroscience 10: 100–112.
5. KatyalS, McKinnonPJ (2008) DNA strand breaks, neurodegeneration and aging in the brain. Mech Ageing Dev 129: 483–491.
6. FuD, CalvoJA, SamsonLD (2012) Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 12: 104–120.
7. CrosbiePA, WatsonAJ, AgiusR, BarberPV, MargisonGP, et al. (2012) Elevated N3-methylpurine-DNA glycosylase DNA repair activity is associated with lung cancer. Mutat Res 732: 43–46.
8. CerdaSR, TurkPW, ThorAD, WeitzmanSA (1998) Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in breast cancer. FEBS Lett 431: 12–18.
9. Leitner-DaganY, SevilyaZ, PinchevM, KramerR, ElingerD, et al. (2012) N-Methylpurine DNA Glycosylase and OGG1 DNA Repair Activities: Opposite Associations With Lung Cancer Risk. J Natl Cancer Inst 104(22):1765–1769 doi:10.1093/jnci/djs445.
10. RobertsonAB, KlunglandA, RognesT, LeirosI (2009) DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci 66: 981–993.
11. BoiteuxS, GuilletM (2004) Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA Repair (Amst) 3: 1–12.
12. AndrabiSA, DawsonTM, DawsonVL (2008) Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci 1147: 233–241.
13. SchaaperRM, KunkelTA, LoebLA (1983) Infidelity of DNA synthesis associated with bypass of apurinic sites. Proc Natl Acad Sci U S A 80: 487–491.
14. PagèsV, JohnsonRE, PrakashL, PrakashS (2008) Mutational specificity and genetic control of replicative bypass of an abasic site in yeast. Proc Natl Acad Sci U S A 105: 1170–1175.
15. AvkinS, AdarS, BlanderG, LivnehZ (2002) Quantitative measurement of translesion replication in human cells: Evidence for bypass of abasic sites by a replicative DNA polymerase. Proc Natl Acad Sci U S A 99: 3764–3769.
16. GoodmanMF, CreightonS, BloomLB, PetruskaJ, KunkelTA (1993) Biochemical Basis of DNA Replication Fidelity. Critical Reviews in Biochemistry and Molecular Biology 28: 83–126.
17. StraussBS (1991) The ‘A rule’ of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? Bioessays 13: 79–84.
18. SobolRW, PrasadR, EvenskiA, BakerA, YangX-P, et al. (2000) The lyase activity of the DNA repair protein [beta]-polymerase protects from DNA-damage-induced cytotoxicity. Nature 405: 807–810.
19. SobolRW, KartalouM, AlmeidaKH, JoyceDF, EngelwardBP, et al. (2003) Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. J Biol Chem 278: 39951–39959.
20. SaparbaevM, LavalJ (1994) Excision of hypoxanthine from DNA containing dIMP residues by the Escherichia coli, yeast, rat, and human alkylpurine DNA glycosylases. Proc Natl Acad Sci U S A 91: 5873–5877.
21. EngelwardBP, WeedaG, WyattMD, BroekhofJL, de WitJ, et al. (1997) Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc Natl Acad Sci U S A 94: 13087–13092.
22. GallagherPE, BrentTP (1984) Further purification and characterization of human 3-methyladenine-DNA glycosylase. Evidence for broad specificity. Biochim Biophys Acta 782: 394–401.
23. HangB, SingerB, MargisonGP, ElderRH (1997) Targeted deletion of alkylpurine-DNA-N-glycosylase in mice eliminates repair of 1,N6-ethenoadenine and hypoxanthine but not of 3,N4-ethenocytosine or 8-oxoguanine. Proc Natl Acad Sci U S A 94: 12869–12874.
24. MiaoF, BouzianeM, O'ConnorTR (1998) Interaction of the recombinant human methylpurine-DNA glycosylase (MPG protein) with oligodeoxyribonucleotides containing either hypoxanthine or abasic sites. Nucleic Acids Res 26: 4034–4041.
25. O'ConnorTR (1993) Purification and characterization of human 3-methyladenine-DNA glycosylase. Nucleic Acids Research 21: 5561–5569.
26. LeeCY, DelaneyJC, KartalouM, LingarajuGM, Maor-ShoshaniA, et al. (2009) Recognition and processing of a new repertoire of DNA substrates by human 3-methyladenine DNA glycosylase (AAG). Biochemistry 48: 1850–1861.
27. FuD, SamsonLD (2012) Direct repair of 3,N(4)-ethenocytosine by the human ALKBH2 dioxygenase is blocked by the AAG/MPG glycosylase. DNA Repair (Amst) 11: 46–52.
28. RothRB, SamsonLD (2002) 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res 62: 656–660.
29. MeiraLB, Moroski-ErkulCA, GreenSL, CalvoJA, BronsonRT, et al. (2009) Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. Proc Natl Acad Sci U S A 106: 888–893.
30. RouleauM, PatelA, HendzelMJ, KaufmannSH, PoirierGG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293–301.
31. SchreiberV, DantzerF, AmeJC, de MurciaG (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517–528.
32. KrishnakumarR, GambleMJ, FrizzellKM, BerrocalJG, KininisM, et al. (2008) Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies Transcriptional Outcomes. Science 319: 819–821.
33. KrausWL, LisJT (2003) PARP Goes Transcription. Cell 113: 677–683.
34. El-KhamisySF, MasutaniM, SuzukiH, CaldecottKW (2003) A requirement for PARP1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Research 31: 5526–5533.
35. MassonM, NiedergangC, SchreiberV, MullerS, Menissier-de MurciaJ, et al. (1998) XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage. Mol Cell Biol 18: 3563–3571.
36. VidalAE, BoiteuxS, HicksonID, RadicellaJP (2001) XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. Embo J 20: 6530–6539.
37. AhelD, HořejšíZ, WiechensN, PoloSE, Garcia-WilsonE, et al. (2009) Poly(ADP-ribose)–Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1. Science 325: 1240–1243.
38. TiminszkyG, TillS, HassaPO, HothornM, KustatscherG, et al. (2009) A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol 16: 923–929.
39. GottschalkAJ, TiminszkyG, KongSE, JinJ, CaiY, et al. (2009) Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci USA 106: 13770–13774.
40. HeeresJT, HergenrotherPJ (2007) Poly(ADP-ribose) makes a date with death. Curr Opin Chem Biol 11: 644–653.
41. JozaN, PospisilikJA, HangenE, HanadaT, ModjtahediN, et al. (2009) AIF: not just an apoptosis-inducing factor. Ann N Y Acad Sci 1171: 2–11.
42. SenejaniAG, DalalS, LiuY, NottoliTP, McGrathJM, et al. (2012) Y265C DNA polymerase beta knockin mice survive past birth and accumulate base excision repair intermediate substrates. Proc Natl Acad Sci U S A 109: 6632–6637.
43. TangJ-b, SvilarD, TrivediRN, WangX-h, GoellnerEM, et al. (2011) N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro-Oncology 13: 471–486.
44. TangJ-b, GoellnerEM, WangX-h, TrivediRN, St CroixCM, et al. (2010) Bioenergetic Metabolites Regulate Base Excision Repair–Dependent Cell Death in Response to DNA Damage. Molecular Cancer Research 8: 67–79.
45. LiuL, GersonSL (2004) Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5: 623–627.
46. WilsonD, SimeonovA (2010) Small molecule inhibitors of DNA repair nuclease activities of APE1. Cellular and Molecular Life Sciences 67: 3621–3631.
47. JelezcovaE, TrivediRN, WangX-h, TangJ-b, BrownAR, et al. (2010) Parp1 activation in mouse embryonic fibroblasts promotes Pol [beta]-dependent cellular hypersensitivity to alkylation damage. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 686: 57–67.
48. TrivediRN, WangX-h, JelezcovaE, GoellnerEM, TangJ-b, et al. (2008) Human Methyl Purine DNA Glycosylase and DNA Polymerase β Expression Collectively Predict Sensitivity to Temozolomide. Molecular Pharmacology 74: 505–516.
49. KisbyGE, LesselrothH, OlivasA, SamsonL, GoldB, et al. (2004) Role of nucleotide- and base-excision repair in genotoxin-induced neuronal cell death. DNA Repair (Amst) 3: 617–627.
50. KisbyGE, OlivasA, ParkT, ChurchwellM, DoergeD, et al. (2009) DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst) 8: 400–412.
51. WangZQ, AuerB, StinglL, BerghammerH, HaidacherD, et al. (1995) Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes & Development 9: 509–520.
52. TarantinoLM, GouldTJ, DruhanJP, BucanM (2000) Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mammalian Genome 11: 555–564.
53. BrooksSP, PaskT, JonesL, DunnettSB (2004) Behavioural profiles of inbred mouse strains used as transgenic backgrounds. I: motor tests. Genes Brain Behav 3: 206–215.
54. LiuC, TuY, YuanJ, MaoX, HeS, et al. (2012) Aberrant Expression of N-Methylpurine-DNA Glycosylase Influences Patient Survival in Malignant Gliomas. J Biomed Biotechnol 2012: 760679 doi: 10.1155/2012/760679.
55. AgnihotriS, GajadharAS, TernamianC, GorliaT, DiefesKL, et al. (2012) Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. The Journal of Clinical Investigation 122: 253–266.
56. FishelML, HeY, SmithML, KelleyMR (2007) Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 13: 260–267.
57. GouldE (2007) How widespread is adult neurogenesis in mammals? Nat Rev Neurosci 8: 481–488.
58. DurkaczB, OmidijiO, GrayD, ShallS (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283: 593–593.
59. BryantHE, SchultzN, ThomasHD, ParkerKM, FlowerD, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913–917.
60. FarmerH, McCabeN, LordCJ, TuttANJ, JohnsonDA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917–921.
61. Mégnin-ChanetF, BolletM, HallJ (2010) Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cellular and Molecular Life Sciences 67: 3649–3662.
62. HainceJ-F, RouleauM, HendzelMJ, MassonJ-Y, PoirierGG (2005) Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends in Molecular Medicine 11: 456–463.
63. StromCE, JohanssonF, UhlenM, SzigyartoCA, ErixonK, et al. (2011) Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 39: 3166–3175.
64. KedarPS, StefanickDF, HortonJK, WilsonSH (2012) Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts. Molecular Cancer Research 10: 360–368.
65. MaW, HalwegCJ, MenendezD, ResnickMA (2012) Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein–Barr virus. Proceedings of the National Academy of Sciences 109: 6590–6595.
66. MuraiJ, HuangS-yN, DasBB, RenaudA, ZhangY, et al. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Research 72: 5588–5599.
67. StromCE, JohanssonF, UhlenM, Al-Khalili SzigyartoC, ErixonK, et al. (2010) Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 39(8): 3166–75 doi: 10.1093/nar/gkq1241.
68. HottigerMO, HassaPO, LüscherB, SchülerH, Koch-NolteF (2010) Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends in Biochemical Sciences 35: 208–219.
69. ZongWX, DitsworthD, BauerDE, WangZQ, ThompsonCB (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18: 1272–1282.
70. XuY, HuangS, LiuZG, HanJ (2006) Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J Biol Chem 281: 8788–8795.
71. HaHC, SnyderSH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96: 13978–13982.
72. EliassonMJ, SampeiK, MandirAS, HurnPD, et al. (1997) Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 10: 1089–1095.
73. MandirAS, PoitrasMF, BerlinerAR, HerringWJ, GuastellaDB, et al. (2000) NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase. J Neurosci 20: 8005–8011.
74. YangZ, ZingarelliB, SzaboC (2000) Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13: 60–66.
75. SahabogluA, TanimotoN, KaurJ, Sancho-PelluzJ, HuberG, et al. (2010) PARP1 Gene Knock-Out Increases Resistance to Retinal Degeneration without Affecting Retinal Function. PLoS ONE 5: e15495 doi:10.1371/journal.pone.0015495.
76. LiC, WangL, KernTS, ZhengL (2012) Inhibition of poly(ADP-ribose) polymerase inhibits ischemia/reperfusion induced neurodegeneration in retina via suppression of endoplasmic reticulum stress. Biochemical and Biophysical Research Communications 423: 276–281.
77. Al-AttarA, GossageL, FareedKR, ShehataM, MohammedM, et al. (2010) Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer 102: 704–709.
78. SweasyJB, LangT, DiMaioD (2006) Is Base Excision Repair a Tumor Suppressor Mechanism? Cell Cycle 5: 250–259.
79. StarcevicD, DalalS, SweasyJB (2004) Is There a Link Between DNA Polymerase Beta and Cancer? Cell Cycle 3: 996–999.
80. ZarembaT, KetzerP, ColeM, CoulthardS, PlummerER, et al. (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101: 256–262.
81. HaoB, WangH, ZhouK, LiY, ChenX, et al. (2004) Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64: 4378–4384.
82. LockettKL, HallMC, XuJ, ZhengSL, BerwickM, et al. (2004) The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64: 6344–6348.
83. ZhangX, MiaoX, LiangG, HaoB, WangY, et al. (2005) Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65: 722–726.
84. BacaliniMG, TavolaroS, PeragineN, MarinelliM, SantangeloS, et al. (2012) A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. Experimental Hematology 40: 197–206.
85. HollemanA, BoerMLd, KazemierKM, BeverlooHB, von BerghARM, et al. (2005) Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 106: 1817–1823.
86. DeichmannWB, LeBlancTJ (1943) Determination of the approximate lethal dose with about six animals. Journal of Industrial Hygiene and Toxicology 25: 415–417.